Braxia Scientific (XCNQ:BRAX) Debt-to-Equity : -1.74 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Braxia Scientific Debt-to-Equity?

Braxia Scientific's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.14 Mil. Braxia Scientific's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.50 Mil. Braxia Scientific's Total Stockholders Equity for the quarter that ended in Dec. 2023 was C$-0.37 Mil. Braxia Scientific's debt to equity for the quarter that ended in Dec. 2023 was -1.74.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Braxia Scientific's Debt-to-Equity or its related term are showing as below:

XCNQ:BRAX' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.74 Med: 0.01 Max: 1.22
Current: -1.74

During the past 3 years, the highest Debt-to-Equity Ratio of Braxia Scientific was 1.22. The lowest was -1.74. And the median was 0.01.

XCNQ:BRAX's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs XCNQ:BRAX: -1.74

Braxia Scientific Debt-to-Equity Historical Data

The historical data trend for Braxia Scientific's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Braxia Scientific Debt-to-Equity Chart

Braxia Scientific Annual Data

Trend

Mar21

Mar22

Mar23

Debt-to-Equity

0.01

0.02

0.13

Braxia Scientific Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial												0.03	0.13	0.25	1.22	-1.74

Competitive Comparison of Braxia Scientific's Debt-to-Equity

For the Biotechnology subindustry, Braxia Scientific's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Braxia Scientific's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Braxia Scientific's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Braxia Scientific's Debt-to-Equity falls into.

Braxia Scientific Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Braxia Scientific's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.076	+	0.131)	/	1.605
	=	0.13

Braxia Scientific's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.136	+	0.501)	/	-0.366
	=	-1.74

Braxia Scientific (XCNQ:BRAX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Braxia Scientific Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Braxia Scientific's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Braxia Scientific (XCNQ:BRAX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Braxia Scientific Corp (XCNQ:BRAX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

BRAXF:USA 4960:Germany

Address

700 Bay Street, Suite 1903, Toronto, ON, CAN, M5G 1Z6

Website

https://www.braxiascientific.com

Braxia Scientific Corp is a research-driven medical solutions company that aims to reduce the illness burden of brain-based mental disorders such as depressive disorder among others. It is primarily focused on owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and research activities related to discovering and commercializing novel drugs and delivery methods. The company develops ketamine and psilocybin derivatives and other psychedelic products from its IP development platform.

Braxia Scientific (XCNQ:BRAX) Headlines

No Headlines